ORAMED PHARMACEUTICALS INC. (ORMP)
CIK 1176309 · all EDGAR filings →
Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.
Shares outstanding over time
Latest: 41.6M shares as of Aug 10, 2026 (10-Q). Share count fell from 86.5M to 7.2M between Dec 19, 2012 and Apr 10, 2013, a pattern consistent with a reverse split (roughly 1-for-12); simultaneous issuance can skew the raw ratio, so confirm in the filings. The red bar marks the cliff.
Cash runway
Going-concern warning
auditor flagged substantial doubt
The company itself flagged going-concern doubt in a filing.
Full breakdown: cash runway tool · source filing →
Warrants
| Tranche | Warrants | Exercise price | Term | Notes |
|---|---|---|---|---|
| ALPHA Tau Warrants | 3.2M | $3.474 | — | — |
| Note Warrants | 1.7M | $13.8 | — | — |
| Share Purchase Warrants | 1.3M | $5.4 | — | — |
| Prefunded Warrants | 1.0M | $0.0001 | — | — |
| Tranche B Warrants | 207,143 | $20 | — | — |
| Warrant | 20,000 | not tagged | — | — |
Tranches exactly as the company dimensioned them in its 10-Q filed Aug 10, 2026 →. Groupings can overlap (a “Series E and F” row is not additive with a “Series E” row), so do not sum this column. A tranche the filer did not tag is absent here, not absent from the cap table. DOWN-ROUND = the filer tagged price-protection accounting scoped to that tranche.
Warrants outstanding: 3.4M underlying shares, as reported Aug 31, 2020 (10-K).
Reported exercise price: $4.13 (aggregate figure as tagged; individual tranches vary).
Balance-sheet fair value of warrants: $637,182 as of Aug 31, 2012.
Rough fully diluted estimate: 45.0M = 41.6M O/S + 3.4M warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.
Convertible notes
| Note | Principal | Carrying | Conv. price | Rate | If converted |
|---|---|---|---|---|---|
| Senior Secured Convertible Notes | not tagged | — | $5.4 | — | — |
| Secured Promissory Note | not tagged | — | $5.4 | — | — |
Notes exactly as the company dimensioned them in its 10-Q filed Aug 10, 2026 →. Principal is face amount as tagged, not what remains after repurchases unless the filer updated the tag. A note the filer did not dimension is absent here, not absent from the balance sheet; the exhibits stay the ground truth.
Fully diluted build-up
Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.
| Shares outstanding | 41.6M | Aug 10, 2026 |
| + ALPHA Tau Warrants (if exercised) | 3.2M | Jun 30, 2026 |
| + Note Warrants (if exercised) | 1.7M | Mar 25, 2026 |
| + Share Purchase Warrants (if exercised) | 1.3M | Jun 30, 2026 |
| + Prefunded Warrants (if exercised) | 1.0M | Jun 30, 2026 |
| + Tranche B Warrants (if exercised) | 207,143 | Feb 19, 2026 |
| + Warrant (if exercised) | 20,000 | Dec 31, 2025 |
| Fully diluted estimate | 49.0M | +17.9% vs O/S |
Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.
Registrations and offerings
Last 12 months: 0 executed · 0 registered.
Full history and shelf status: offering checker · S-3 shelf checker
Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.
Keep going: float checker · offering calendar · short-squeeze screener · full ORMP workspace